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Abstract 
 
Growth factors (GFs) are naturally occurring protenatious substance, secreted by surrounding 
cells essentially required for cellular growth, maturation, proliferation, differentiation and 
healing of injury. However, we have limited clinical applications due to lack of appropriate 
delivery systems and biomaterial carriers. Many conventional delivery systems are there to 
deliver GFs like polymeric particle, emulsions, and dendrimers. In conventional approaches 
proteins (GFs, enzyme, etc.) undergo several process and storage-related stresses throughout 
the life of the product that can result in significant degradation and loss of activity. Usually 
protein-containing microparticles are prepared by the double emulsion method, such as 
water/oil/water (W/O/W), solid/oil/water (S/O/W) and water/oil/oil (W/O/O). In the primary 
emulsion the protein encounters an aqueous organic interface which causes denaturation of the 
protein. Added to this are other process related stresses like, high homogenization speed, 
sonication and temperature. In order to address the aforementioned problems, we have 
introduced a novel method of protein encapsulation. The sugar glass nanoparticle system 
(SGnPs) is produced by incorporating sugars and other stabilizers along with the proteins in 
inverse micelles. This will ensure the preservation of activity of the encapsulated protein, by 
protecting it from the various process related stresses. Further these SGnPs are used for 
preparation of polymeric microparticles using the aforementioned conventional methods 
(W/O/W and W/O/O) for long time storage and control the release pattern. By using of SGnPs 
for GFs delivery we have achieved 100% encapsulation efficiency and sustained release, only 
18% has released in 30 days.  
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Nomenclature 
 
GFs- Growth Factors 
SGnPs- Sugar Glass nanoparticle 
W-O-W- Water in Oil in Water emulsion 
W-O-O- Water in Oil in Oil emulsion 
SGnPs-O-W- SGnPs in Oil in Water emulsion (Novel approach) 
SGnPs-O-O- SGnPs in Oil in Oil (Novel approach) 
PLGA- Poly (lactic-co-glycolic acid) 
SEM- Scanning electron microscopy 
DLS- Dynamic light scattering 
PDS- Protein delivery system 
Fig. -Figure 
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Chapter 1 
Introduction 
1.1 Tissue engineering and Regenerative medicine 
Regenerative medicine is a branch of translational research in field of tissue engineering which 
combines the principles of biology and engineering to achieve the goal of the regeneration, 
replacement, restore or establish normal function of damaged or injured body 
tissues[1]. Regenerative medicine promises not only the engineering of damaged cells, tissues 
and organs via stimulating the body's own repair mechanisms to restore its normal function but 
also includes the possibility of growing cells, tissues and organs in the laboratory and safely 
implanting them when the body cannot heal itself.[2,3] 
Regenerative medicine for tissue regeneration consists of cells with proliferative and 
differentiative potential, Signaling molecules (GFs), GF delivery vehicle, culture medium and 
bioreactor [4]. In the most frequent paradigm of tissue engineering, isolated living cells are used 
to develop biological substitutes for the replacement or restoration of cell, tissue or organ 
functions. Generally, cells are seeded on bio-absorbable scaffolds, a tissue is developed in vitro, 
and the construct is implanted in the appropriate anatomic location as a prosthesis [4, 5]. Cells 
used in tissue engineering may come from a variety of sources including application-specific 
differentiated cells from the patients themselves (autologous), human donors (allogeneic) or 
animal sources (xenogeneic), or undifferentiated cells comprising progenitor or stem cells [5, 6]. 
 
1.2 Growth Factors 
Growth factors are naturally occurring a group of proteins that stimulate the growth of 
specific tissues and play an important role in promoting cellular differentiation, cell division, 
migration, metabolism and healing [7, 8]. During the study of different biological substances on 
cell/tissue researchers found some peptides whose functions were totally different form 
previous known functions i.e. hormone and enzymatic and were involved in stimulating 
cellular growth so they called Growth factor. GFs play an important role in wound healing, 
tissue regeneration by stimulating granulation tissue formation, modulating the inflammatory 
responses, matrix formation, remodeling, re-epithelization process and promoting angiogenesis 
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[9, 10]. In culture, growth factors are rate limiting factor for proliferation because they deplete 
more rapidly than any other media components [11, 12]. 
GFs stimulate cell proliferation and other responses through binding to specific cell membrane 
receptors (Fig-1.1). The interaction of the GFs to its corresponding receptor is highly specific, 
which ensures delivery of a particular message to a distinct population of cells. GFs stimulate 
receptor to transduce secondary signals and activate intracellular signal transduction pathways 
which controls various aspects of subcellular biology and cellular function (fig- 1.1) [13]. Unlike 
hormones GFs do not usually act in an endocrine manner; they presumably diffuse short-range 
through intercellular spaces and act locally [14].  
 
Fig.1.1- Mechanism of action of growth factors. GFs bind to their respective receptors and initiate the signaling 
pathways that activate signaling molecules. Signaling molecules can either activate proteins present in the 
cytoplasm or induce transcription of new proteins through the activation of transcription factors for different 
cellular responses such as growth, differentiation, migration, etc. P= phosphorylation. 
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Application of growth factors may not be much effective without proper delivery vehicle, 
because of their short half-life in vivo and the potential toxicity and systemic effects of bolus 
delivery [15]. 
Organs transplantation or synthetic implants are the currently available methods to treat loss of 
tissues and organs but still there is a continue demand of a new solutions and approaches for 
tissues failure since the definitive solution is too far to be achieved, and for this reason 
regenerative medicine and tissue engineering are becoming as the alternative solution to repair 
or regenerate damaged tissue [16, 17]. 
The main goal of this experiment is to develop a vehicle releasing growth factors to stimulate 
desired cell response in order to enhance and accelerated tissue healing [16]. 
 
1.3 Biomaterials for Growth Factor Delivery 
 
A biomaterial can be defined as a nonviable substance that has been engineered to interact 
biological system, used alone or as part of a complex system, for a medical purpose either as 
therapeutic or diagnostic substance [18. 19]. Many biomaterials have been discovered, developed 
and used by researchers over the years as carrier for growth factors [19]. 
These materials can be derived either from natural resources or synthesize in laboratory using 
a variety of chemical approaches. 
1.3.1 Natural Materials 
Being natural originated, these materials minimizes chronic inflammation and rejection by 
immune system and also ensure to develop a delivery systems that functions at the molecular 
level. Most of natural materials are water soluble that allows mild fabrication conditions which 
are harmless to the bioactivity of the loaded growth factor. Sometimes these natural material 
also have some intrinsic biological activity that may be induce to regeneration. 
Commonly used natural material as growth factor carriers are silk, collagen, gelatin, chitosan, 
alginate, agarose, hyaluronic acids, fibrin, elastin, starch, and carrageenan [20, 21, 22]. 
 .  
1.3.2 Synthetic Materials 
The major advantage of using synthetic materials over natural is that they can be synthesized 
or modified based on the desired properties beneficial to clinical outcomes and additionally 
composites of different materials can be used to optimize the individual characteristics of 
biomaterial and improve the efficiency of growth factor delivery system. Commonly used 
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synthetic biomaterial as GF carrier are Poly-l-lysine (PLL), poly-lactic acid (PLA), 
polyglycolic acid (PGA) their copolymers polylactic-co-glycolic acid (PLGA), poly-
gammaglutamic acid polyethyleneimine (PEI), polyethylene glycol poly-N-
isopropylacrylamide (pNiPAAm), poly-hydroxyethylmethacrylate (pHEMA), poly-
caprolactone (PCL) [20, 21, 23]. 
 
1.4 Strategies for Growth Factor Delivery 
 
Polymers can be formulated into many different physical structures for developing growth 
factor delivery system like scaffolds, hydrogels, particulate system and nanofibers [27, 28, 29]. 
GFs are encapsulated in polymer matrix either by absorption or by covalent immobilization. In 
culture GFs are released either by diffusion from the matrix or by degradation of the 
biomaterial. In most of the cases, these kind of system show burst release profile dependent on 
the degradation rate which is difficult to control. Researchers have made several modifications 
in the biomaterials to control the release pattern of GFs [24, 25, 26]. 
Particulate systems are distinct from other aforementioned delivery systems and have 
advantage over them because of their reduced size that range varies nm to µm and other unique 
properties are such as solubility, biodistribution, immunogenicity, and release characteristics. 
The very important advantage of particulate system is its smaller size that ensure the ability to 
target a specific tissue with minimal distribution to normal tissues [30, 31]. Hence, particulate 
delivery systems will open possibilities of addressing the failure of traditional therapeutics in 
regenerative medicine and suggest some modification to curb limitations.  
 
1.5 Delivery of Growth Factors 
A variety of growth factor proteins have been available in large quantities as a result of 
advances in biotechnology. Many Protein delivery system (PDS) such as Hydrogels, Scaffolds, 
Nanofibers, Polymeric Nanosphere/ Microspheres, Lipid nanoparticles (Liposomes) have been 
developed to deliver growth factors to a specific organ or tissue systems with controlled release 
of growth factors for days to months [27, 28, 29]. For delivery of growth factors generally we use 
biodegradable polymers such as poly lactic acid (PLA), poly glycolic acid (PGA), and poly 
lactic-co-glycolic acid (PLGA) because the release profile of loaded growth factor mainly 
depends on the degradation kinetics of coating polymer and it is easy to understand how we 
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can change the release profile by changing the composition of polymer [20-23]. We can change 
the degradation kinetics by changing the ratio of lactic acid and glycolic acid. It may not be 
true always because other excipient also affect the release kinetics but the polymer composition 
is always a dominant factor [32, 33]. An ideal delivery system should have reasonably high 
protein encapsulation efficiency, loading capacity, and sustained release of the loaded protein 
with retained bioactivity [27, 29].  
 
1.6 Common approaches to develop delivery systems for GFs 
 
1. Double Emulsion technique 
 Water in Oil in Water (W-O-W) 
 Water in Oil in Oil (W-O-O) 
 Solis in Oil in Oil (SGNPS-O-O) 
 Solid in Oil in Water (W-O-W) 
2. Spray drying and Spray freeze-drying technique 
3. Ultrasonic Atomization technique  
4. Electrospray technique 
5. Microfluidic technique 
6. Pore-closing and Thermoreversible-Gel technique 
7. Microfabrication technique 
Double emulsion technique consists solvent diffusion or solvent evaporation mechanism. 
In this method we use two immiscible solvent are homogenized for making emulsion and 
this emulsion again disperse in another immiscible solvent [34, 36, 57]. Solvent evaporation 
takes place in W-O-W while diffusion takes place in W-O-O (Fig-1.2). 
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Fig.1.2- Double emulsion technique for PLGA microparticles. For primary emulsion DCM 
was used, for secondary emulsion 2.5 % PVA solution (W-O-W) and Light liquid paraffin 
oil (W-O-O) used. 
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Chapter 2 
 
Literature Review 
 
In 1999 Yi-Yan Yang et al. investigated the important parameters to fabricate PDLLA (Poly 
(DL-lactic acid)), PDLLGA (Poly (DL-lactic-co-glycolic acid) 65: 35 and blends of PDLLGA 
65: 35 and PEG microspheres having BSA by double-emulsion (water-in-oil-in-water) solvent 
extraction/evaporation method. Release profiles of microspheres were carried at 22oC in order 
to develop controlled release delivery system for marine fishes. They have investigated various 
factors that affects the size of microspheres, encapsulation efficiency, morphology of 
microsphere, release profile, and BSA distribution within microspheres. These factors include 
preparation temperature, solvent evaporation rate, ratio of oil phase to internal water phase, 
and polymer concentration. Microspheres were developed at a low volume ratio of oil phase to 
internal water phase and a low polymer concentration. Microspheres had a large surface area, 
a low bulk density, resulting in a high initial burst and a fast release of BSA. Temperature 
majorly affects solvent extraction/evaporation and mechanism of phase-inversion. It was 
reported that microspheres were fabricated at 4 and 380C yield the highest encapsulation 
efficiency (52.0%) and lowest initial BSA release (18.8%), while microspheres produced at 
220C showed the low encapsulation efficiency and high initial burst. In this experiment they 
showed that encapsulation efficiency, initial burst and release profile of microspheres can be 
controlled by changing preparation conditions such as temperature, removal rate of solvent, 
and volume ratio of oil to internal water [35]. 
 
In 2008 Asep Bayu Dani Nandiyanto et al. developed spherical mesoporous silica particles 
having pore size and outer particle diameter in the nanometer range by water/oil phase using 
organic templates method. In this method simultaneous hydrolytic condensation of 
tetraorthosilicate forms silica and polymerization of styrene forms polystyrene. In this method 
an amino acid catalyst, octane hydrophobic-supporting reaction component, and 
cetyltrimethylammonium bromide surfactant were used. After removal of the organic 
components by calcinations, we get mesoporous silica particles. Unlike other common 
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mesoporous methodology, by this method we get particle with small pore size (4–15 nm) and 
particle diameter (20–80 nm). By changing the styrene concentration we can control pore size 
and changing in the concentration of the hydrophobic molecules can control outer diameter of 
the particle. Mesoporous particles with controllable pore size (4–15 nm) and outer diameter 
(20–80 nm) of Hiroshima Mesoporous Material (HMM) were successfully prepared in a 
water/oil phase using an organic template method. The adsorption properties of the prepared 
porous silica particle were too good in comparison with previous non-porous silica particles 
[37, 38]. 
 
In 2008 DONG Xiao Qing et al. prepared recombinant human epidermal growth factor (rhEGF) 
loaded poly-lactic-co-glycolic acid (PLGA) microspheres by w/o/w extraction–evaporation 
technique. Transmission electron microscopy (TEM) and particle size distribution by laser 
particle analyzer used for the characterization of microspheres morphology. Release profile, 
the proliferation and therapeutic effects of rhEGF-loaded PLGA microspheres were all studied. 
Those microspheres had a narrow size distribution and a high GF encapsulation efficiency 
(85.6%). In Experiment those RhEGF-loaded microspheres showed better growth rate of 
fibroblasts and wound healing in comparison to pure rhEGF. Sustained-release microspheres 
encapsulating rhEGF in the polymer, showed nontoxicity, sustained-release profile and higher 
activity of rhEGF [39].  
 
In 2010 Yuejie Chu et al. prepared nanoparticles for delivery of recombinant human epidermal 
growth factor (rhEGF) using poly (lactic-co-glycolic acid) by double-emulsion method. 
Transmission electron microscope (TEM) and laser analyzer with zeta potential were used for 
the morphology of the nanoparticles and particle size distribution. Enzyme-linked 
immunosorbent assays (ELISA) was performed to determine the rhEGF encapsulation 
efficiency and release profile. The average particle size of rhEGF nanoparticles was around 
193.5nm (diameter), and the particle size distribution was uniform. The encapsulation 
efficiency was 85.6% and rhEGF showed release lasted within 24 hours. Compared with other 
delivery modality the rhEGF nanoparticles showed the highest proliferation rate of fibroblast, 
and fastest healing rate. The result of this experiment showed that controlled release of rhEGF 
encapsulated in the nanoparticles enhanced rhEGF effects for cell proliferation, shorten the 
wound healing time and a controlled release of rhEGF for up to 24 hours without disturbing its 
biological activity [40]. 
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In 2010 Yanfang Yang et al. prepared porous poly (L-lactide-co-glycolide) (PLGA)/b-
tricalcium phosphate scaffolds containing dexamethasone (Dex) and bovine serum albumin 
(BSA) by spray-drying and PLGA microspheres containing Dex or BSA were prepared by 
double emulsion/ solvent evaporation method. Release studies of microspheres prepared from 
PLGA in 3:1 molar ratio of L-lactide/glycolide and 89.5 kDa prolonged release profiles 
comparison with particles those prepared from PLGA in 1:1 L-lactide/glycolide molar ratio 
and 30.5 kDa. Addition of poly ethylene glycol (PEO) with PLGA could improve the 
encapsulation efficiency and reduce the release rate [41]. 
 
In 2010 Oks and Karal-Yilmaz et al. synthesized Poly (lactic-co-glycolic acid; PLGA), 
microparticles encapsulating the human recombinant vascular endothelial growth factor 
(rhVEGF) to achieve rhVEGF sustained release pattern by a water-in-oil-in-water (w/o/w) 
double emulsion/solvent evaporation method. The microparticles were having diameters of 10–
60 mm and the encapsulation efficiency was between 46% and 60%. The microparticles were 
characterized by particle size distribution, environmental scanning electron microscopy 
(ESEM), light microscopy, encapsulation efficiency and their degradation rate. Mw (Mw), 
composition and crystallinity of copolymer are the factors that affects the degradation rate and 
release profile of PLGA microparticles. The mass loss (%) during PLGA microparticles 
degradation study shows 2% after 7 days, 8% after 14 days and significant mass loss begins 
approximately after 21 days which reaches up to 92% in 35 days. The microparticles showed 
slower rate of degradation up to 21 days and after this degradation rate increases over the 25 
days [42]. 
 
In 2013 Garazi Gainza et al. developed rhEGF-loaded PLGA-Alginate microspheres by 
modified w/o/w double emulsion/solvent evaporation method. Different formulations were 
evaluated for the optimization of MSs properties by adding sodium chloride (NaCl) to the 
surfactant solution and adding alginate as a second polymer. The characterization of the 
prepared MSs showed that incorporation of alginate with PLGA increased the encapsulation 
efficiency. Results showed that the addition of NaCl increases the EE and also make the particle 
surface smooth and even. After loading of 1% rhEGF in to PLGA-Alginate MSs, the particles 
were sterilized by gamma radiations for in vivo studies. This experiment showed the 
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advantages of using NaCl and alginate incorporation during the microsphere preparation for 
achieving a greater EE and sustained release profile [43]. 
 
In 2011 J. Giri et al. prepared sugar glass nanoparticle for encapsulating Horse reddish 
Peroxidase (HRP) by inverse emulsion method. In this method they made inverse emulsion of 
HRP with trehalose in AOT- Isooctane solution. This emulsion was flash freezed in Liq. 
Nitrogen (-1980 C) to get sugar matrix encapsulated HRP. The sugar glass nanoparticles so 
produced showed marked effects in conserving the activity of protein against several process 
related stresses (Fig-5.2). This technique shows sustained as well as prolonged release of 
protein [44].  
In 2015 Peng Zhai et al. encapsulated bovine serum albumin (BSA) in to Poly (lactic-co-
glycolic acid) (PLGA) microspheres and PLGA/alginate composite microspheres by a novel 
double emulsion and solvent evaporation method. It was found that the addition of alginate 
with PLGA and the using surfactant in microsphere preparation has increased the encapsulation 
efficiency and reduced the initial burst release of BSA. Confocal laser scanning microcopy 
(CLSM) showed evenly distribution of PLGA, alginate, and BSA throughout the depths of 
microspheres and no core/shell structure was observed. By scanning electron microscopy 
(SEM) images it can be concluded that PLGA microspheres degrade more quickly than 
PLGA/alginate composite microspheres. In this experiment anti-laminin antibody was loaded 
in to PLGA/alginate microsphere, to know about the preservation of the activity and result 
showed that activity was more preserved in PLGA/alginate microsphere in comparison to 
PLGA microsphere [45]. 
 
In 2015 Xiaojun Zhou et al. synthesized Bone morphogenic protein (BMP-2) peptide 
encapsulated in mesoporous silica nanoparticles (MSNs). First BMP-2 peptide was covalently 
grafted on the surface of MSNs via an amino-silane linker, and then dexamethasone (DEX) 
was loaded into the channel of MSNs to construct nanoparticulate osteogenic delivery system. 
Potency of MSNs were tested with bone mesenchymal stem cells (BMSCs) in vivo resulting 
that the functionalized MSNs have better cyto-compatibility and cellular uptake efficiency than 
that of bare MSNs. The in vitro results also showed that MSNs promoted osteogenic 
differentiation and proliferation of BMSCs in terms of the alkaline phosphatase (ALP) activity, 
calcium deposition, and expression of bone-related proteins and the osteogenic differentiation 
and proliferation of BMSCs can be further enhanced by addition of DEX into MSNs [47]. 
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Table- 2.1 Different protein delivery Systems (PDS) 
 
S/N 
PDS system & Polymer 
composition 
Protein 
encapsulated 
Size of particle Reference 
1 
Mesoporous Silica nano particle 
with DEX 
BMP-2 peptide of 
73-79 residue 
20-80nm 47 
2 PLGA-Alginate microsphere rhEGF 14.95µm 48, 49 
3 Solid lipid nanoparticles (SLN) 
Coenzyme Q10 
 
200nm-4µm 50, 51 
4 
Chitosan oligosaccharide-heparin 
Np 
Stomatal cell 
derived factor-1α 
& vascular 
endothelial GF 
96.2-210.5 nm 
 
52 
5 
Nano and micro chondroitin 
sulphate particles 
Transforming 
growth factor-b1 
and Tumor 
necrosis factor-a 
324.1 ± 8.5 and 
73.2 ± 4.4 nm, 4.3 
± 0.93 µm 
53 
6 
Chitosan and poly (ethylene oxide) 
multifunction nano fibre 
VEGF with plate 
derived GF 
153 ± 36 nm 54 
7 
Low molecular weight 
heparin(LMWH)/protamine (P) 
nano/micro particles 
 100 nm–3 μm 55 
8 Cyclodextrin-PELA fibre bFGF  56 
9 Oil-in-Oil Emulsions  20-100nm 57 
10 
Collagen microsphere and 
fibrilized collagen microsphere 
collagen 2.2-440 µm 58 
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2.1 Challenges in delivery of growth factor from PDS 
 
Though we have developed many advanced PDS but still there are some common problems 
with their release profile i.e. Burst release, Activity loss, Encapsulation efficiency, Duration of 
release, Particle size, Protein loading capacity, bioactivity of the released protein and extent of 
release. The protein release profiles from various PDS can be classified on the basis of the (i) 
Magnitude of burst release, (ii) Extent of protein release, and (iii) The protein release kinetics 
followed by the burst release [44, 59]. 
Clinically successful long-term biodegradable PDS based on micro/nano particles requires 
improvement in the drug loading efficiency, control of the initial burst release, and the ability 
to control the protein release kinetics and another side they undergo several process and storage 
stresses i.e. elevated temperatures, exposure to liquid and solid hydrophobic interfaces, and 
vigorous mechanical agitation etc [44, 59, ]. 
We have developed many approaches to overcome a single problem but none of them was able 
to resolve all problems. For example solid in oil in water emulsion (SGnPs-O-W) was 
developed which is able to avoid hydrophobic interface interaction in comparison to water in 
oil in water emulsion system (w-o-w) but this system has reduced protein loading capacity, and 
burst release. For making SGnPs-O-W we have to freeze dry the protein for loading that tends 
to yield larger protein particle which provide poor dispersion in final delivery product [44]. 
Other approaches such as spray-drying, spray-freeze drying, or freeze drying with polyethylene 
glycol (PEG) have been used to generate smaller stabilizer-bearing protein particles but the 
drawback is a large amount of protein denatures during encapsulation process [59]. 
More recently researchers developed new PDS by precipitating protein in organic solvent but 
it is not good for storage, and not validated for therapeutic protein till now. Thus, the field of 
drug delivery systems for regenerative medicine still has huge scope to discover new 
approaches and new smart solutions to overcome these limitations with the support of materials 
science [60]. 
So the challenge was to develop a PDS that would able to avoid the hydrophobic interface 
interaction, increase the loading capacity, provide the burst free sustained release and increase 
storage and process durability. To achieve all phenomena in a single system we have developed 
new PDS Sugar Glass Nanoparticles (SGnPs) in which we are encapsulating the growth factors 
inside the SGnPs (Fig.5.2) [44]. 
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Chapter 3 
 
Objectives 
 
A. Preparation and characterization of GF encapsulated micro/nano 
particles by conventional emulsion and novel SGnPs methods. 
 
B. Study the encapsulation efficiency of protein into polymer particle. 
 
 
C. Study the release profile of protein from polymeric SGnPs. 
 
D. Determination of activity loss during process. 
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Chapter 4 
Materials 
1. Poly(D-lactic–co glycolic acid) PLGA, Lactide: glycolide-50:50 
(RG502H) , Mw- 7000-17000 Da, Inherent viscosity (dl/g) - 0.16-0.24, 
End group- Free carboxylic acid 
 
2. Poly Vinyl Alcohol (PVA)  high Mw, Average Mw -88,000 - 97,000 Da,   
Hydrolyzed - 87-89% 
3. Organic Solvent- Dicloromethane (Pure) HPLC grade, Mw- 84.93 Da 
 
4. Modal Protein- a) Bovine serum albumin (BSA), Lyophilised powder-96% 
(Agarose gel electrophoresis), Mw- 66000 Da, FITC BSA  
  
5. Surfactant- Span-80 viscosity- 1200-2000 mPa.s, Tween-20  
  
6. Model Enzyme- Horse reddish peroxidase (HRP), Mw- 44000 Da 
 
7. O-phenylenediamine dihydrochloride (OPD) Extrapure , Mw-181.06 Da 
 
8. Hydrogenperoxyde  
 
9. Trizma Hydrochloride (TRIS) 99.0%, Mw- 157.60 Da 
 
10. D(+)Trehalose dehydrate, Mw-378.33 Da 
 
11. Docusate Sodium (AOT)-USP, Mw- 444.56 
 
12. Isooctane (HPLC grade) 
 
13. Light paraffin oil 
  
14. N-Hexane 
 
15. BCA Assay kit 
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Chapter 5  
 
Experiment and Methodology 
 
5.1 Preparation and characterization of GF encapsulated micro/nano 
particles by conventional emulsion and novel SGnPs methods 
 
       5.1.1 Optimization process of conventional method 
 
Here we used two conventional methods for developing novel GF delivery vehicle. First we 
optimized W-O-W and W-O-O double emulsion technique. For this we set some parameters to 
be optimized; are Polymer concentration, Polymer-Protein ratio, Organic-Aqueous phase ratio, 
Continuous phase volume and concentration, Homogenization speed, particle size, loading 
capacity, encapsulation efficiency. 
 
Table 5.1- Optimization of W-O-W double emulsion technique 
S/N BSA 
Con. 
(w/v) 
% 
PLGA 
Con. 
(w/v) 
% 
Homogenization 
speed for 
primary 
emulsion (RPM) 
and Time 
PVA 
Con. 
(w/v)% 
Homogenization 
speed for 
Secondary 
emulsion (RPM) 
Avg. 
Particle 
size 
range 
(µm) 
Encapsulation 
efficiency (%) 
1 5 2.5 12000, 20 Sec 2.0 12000, 5Min. 1.0-2.0 30.71 
2 10 2.5 20000, 20 Sec 2.0 12000, 5Min 1.5-2.5 22.97 
3 2.5 2.5 12000, 1 Min 2.5 12000, 5 Min 1.0-2.0 18.01 
4 2.5 2.5 20000, 1 Min 2.5 12000, 5 Min 1.0-1.5 55.88 
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5.1.2 W-O-W emulsion technique 
 
2.5% mL PVA solution was prepared. 2.5 mg of BSA was dissolved in 200µL of deionized 
water to make a clear suspension. This suspension was added dropwise in to solution of 50mg 
PLGA in 2mL DCM. Homogenize this mixture at 20K for 1 minute to get homogenous, milky 
and stable primary emulsion. This primary emulsion was added dropwise in 50mL of PVA 
solution with continuous homogenization at 12K for 5 minute to make double emulsion. This 
system was kept for continuous stirring for 4.5 hours at 600 rpm to evaporate DCM. After 
evaporation of DCM we get solid PLGA particle suspended in PVA solution. Centrifuge it at 
8K rpm for 15 minutes to get solid particle. Wash these particles with deionized water 3 times. 
These particle were freeze at -80◦C for 3 hours and then immediate kept for lyophilization for 
72 hours. Then particle were preserved at 4◦C for further study [34, 36]. 
 
5.1.3 W-O-O emulsion technique 
 
For W-O-O emulsion technique primary emulsion was made by same procedure like W-O-W 
for secondary emulsion we used 10mL of light liquid paraffin with 100µL of tween-20 instead 
of PVA solution. We add primary emulsion in dropwise manner with continuous 
homogenization at 20k for 5 minutes. We get PLGA particle suspended in paraffin. Keep 
suspension for continuous stirring for 3 hours. To make particle solid and hard add 5mL of n-
hexane with interval of 30 minutes. Centrifuge it at 8000rpm for 15 minutes and wash it 3 times 
with n-hexane. Preserve particles at 4◦C for further process [47, 61]. 
 
5.2  Preparation of Sugar glass nanoparticles (SGnPs) 
 
SGnPs are formed from inverse micelles of AOT [sodium 1, 4-bis (2-ethylhexoxy)-1,4-
dioxobutane- 2-sulfonate] in isooctane. AOT was dissolved in 12 mL of isooctane in a 25 mL 
centrifuged tube to produce a 0.3 to 0.4 mol L-1 solution. Aqueous phase of 0.4 to 0.8 mL 
containing protein and other excipients was then added. The mixture was vortexed for 30 s to 
2 min to obtain a clear suspension. The aqueous phase contained protein with other protein-
specific excipients (e.g., Trehalose sugar, Tween-20, TRIS-HCl). The inverse micelle 
suspension was flash-frozen by slowly injecting it into a 50 mL vial containing liquid nitrogen 
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(N2). The vial with the frozen nanoparticles and isooctane was then lyophilized to evaporate 
isooctane and water (Fig.5.1). After lyophilization, the nanoparticles were washed in isooctane 
by resuspending and subsequently centrifuging them at 400 g for 10 min. This washing process 
was repeated 4 to 5 times and finally the SGnPs dispersion (Fig.5.2) was stored in isooctane 
under desiccation at –20 ° C or –80 ° C for future use [44]. 
 
        
                       Fig.5.1 Solvent trapping system for sugar glass nanoparticle system 
 
 
 
 
 
 
 
 
 
 
 
 
        Fig.5.2- Sugar glass nanoparticle: protein laden in sugar matrix that is coated by surfactant 
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5.3 Encapsulation of SGnPs 
 
These SGnPs are encapsulated in to PLGA polymer by aforementioned double emulsion 
technique to make a proper delivery vehicle for GFs (Fig.5.3). 
 
 
 
 
 
 
Fig.5.3 Novel SGnPs technique for develop delivery vehicle for GFs. Schematic presentation of  
 
SGnPs distribution across the polymer nanoparticle. For primary emulsion DCM was used, for 
secondary emulsion 2.5 % PVA solution (W-O-W) and Light liquid paraffin oil (W-O-O) used. 
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5.3 .1 Study of encapsulation efficiency of protein in polymer particles 
 
For the encapsulation efficiency we have also optimize the process that include optimization 
of polymeric particle digestion, incubation period for protein estimation. For optimizing the 
process we made triplicate batch of PLGA particle of different loading 1%, 5%, 10% and 20%. 
Protein encapsulation efficiency was done by BCA Assay kit. This assay kit contains three 
reagent; A, B, C. For estimation of the protein we made a mixture of A, B and C (BCA solution) 
in the ratio of 25:24:1 respectively [63]. This BCA assay kit shows protein amount in range of 
20 µg/mL to 100 µg/mL. Before calculating encapsulated amount of protein in polymeric 
particles we mad standard curve of protein (20-100 µg/mL) with BCA assay kit (Fig.5.4).  We 
digested 5.0 mg PLGA polymeric particles in DCM and add 2 mL of PBS (pH-7.4) in 8 mL 
culture vial in triplicate manner from each batch. We kept it in incubator-shaker at 370C for 
overnight (16 Hrs.).  
 
5.4 Encapsulation Efficiency (EE): - Part of loaded protein encapsulated into nanoparticle. 
Indirectly it tells the wastage amount of protein during encapsulation. It is also represented in 
percentage. 
 
                   %EE= 
𝐖𝐞𝐢𝐠𝐡𝐭 𝐨𝐟 𝐞𝐧𝐜𝐚𝐩𝐬𝐮𝐥𝐚𝐭𝐞𝐝 𝐩𝐫𝐨𝐭𝐞𝐢𝐧 
𝐰𝐞𝐢𝐠𝐡𝐭 𝐨𝐟 𝐭𝐨𝐭𝐚𝐥 𝐩𝐫𝐨𝐭𝐞𝐢𝐧 𝐮𝐬𝐞𝐝 𝐟𝐨𝐫 𝐞𝐧𝐜𝐚𝐩𝐬𝐮𝐥𝐚𝐭𝐢𝐨𝐧
× 100 
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                                      Fig. 5.4- Standard curve of BSA by using BCA kit 
 
After incubation supernatant part (Aqueous phase) was carefully separated and diluted it 5 
times to bring it with in the range of assay kit. From each vial 150 µL of diluted part was loaded 
in to 96 well plate in triplicate manner and then add 150 µL of BCA solution was added. Well 
plate was covered carefully with paraffin membrane and kept for incubation at 37 0C for 2 
hours. After incubation the protein was estimated by micro plate assay reader. 
 
5.5 Study of release profile of protein from polymeric microparticles 
We did comparatively release profile study of polymeric particle made by conventional method 
as well as by novel method. Microspheres were observed over a period of 30 days in PBS at 
37 °C. The rate of degradation of PLGA microspheres depend on some factors such as Mw of 
polymer, water permeability, porosity, additives, environmental pH. The degradation 
mechanism of PLGA polymer is water penetration into microspheres, the swelling and erosion 
of PLGA microspheres thus subsequent hydrolysis of PLGA chains, which prompts bulk 
erosion of PLGA microspheres. We kept 10 mg of different loading (5 and 20%) PLGA 
particles in eppendorf tube having 1.2 mL of PBS for release study. The sample was collected 
on 0.17. 0.417, 1, 2, 3, 5, 7, 14, 20, 30 days and BSA estimation was done by BCA assay kit.  
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Release study of SGnPs loaded PLGA particle prepared by novel approaches are done in same 
manner as we did for conventional approach.  
 
5.6 Characterization of polymeric particles 
Particle size distribution was analyzed by microscopy (Carl Ziess) and DLS (Beckman 
Coulter). Surface morphology study was done by Scanning electron microscopy (SEM).  To 
know protein distribution in to polymeric matrix we used fluorescein conjugated BSA (FTIC) 
to make particles by conventional and as well as novel method. After formation of particle we 
examined these under fluorescent microscope at 512 nm (Fig.6.13 & 6.14). Each and every 
step of this experiment carried in dark to make sure the fluorescent effect proper. 
Each assay is done in triplicate manner. 
 
5.7 Determination of activity loss during process 
 
For determining the activity loss during process we used HRP as model enzyme which shows 
its activity towards OPD substrate in colorimetric assay at 435 nm [62]. That parameter was also 
optimized. For getting optimized time of incubation we did BCA assay and OPD assay. BCA 
assay showed release of total HRP over the time while OPD assay shows total activity of 
released protein over the time. For the comparison we made HRP standard curve with BCA 
and OPD (Fig.5.5 & 5.6). For this we took 10mg of HRP encapsulated PLGA particles and 
kept in 5mL TRIS-HCl (pH 5.4) at room temperature. Each hour we collected sample and 
estimated the activity. This experiment was carried out in triplicate. 
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                        Fig.5.5 HRP concentration Standard curve by BCA assay kit 
    
  
                       Fig.5.6 HRP activity standard curve with OPD substrate 
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Chapter 6 
Result and Discussion 
6.1 Optimization of W-O-W and W-O-O double emulsion method 
2.5 % BSA solution in DIW, 2.5 % PLGA solution in DCM, aqueous-organic phase ratio-0.1, 
primary emulsion at 20K rpm for 1 minute, secondary emulsion 12K for 5 minute, 50mL of 
2.5% PVA gives highest encapsulation efficiency (55.88%) and average particle size (1.0-
1.5µm) and for W-O-O 10mL of liquid light paraffin, 100µL SPAN-80 was optimized for 
maximum encapsulation efficiency. 
6.2 Morphological study of particle 
6.2.1 Particle size distribution 
By the optical microscopy and DLS showed the particle size 1.0-1.5 µm (Fig.6.1-6.2). 
 
 
                         Fig. 6.1 Particle size distribution by optical microscopy 
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            Fig. 6.2     Average diameter of PLGA particles by DLS 
 
       6.2.2 Surface morphology 
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     Fig.6.3 SEM image of PLGA microparticle by conventional W-O-W emulsion technique. 
   
        Fig.6.4 SEM image of PLGA microparticle by novel SGnPs-O-W emulsion technique. 
 
37 
 
       
          Fig.6.5 SEM image of PLGA microparticle by conventional W-O-O emulsion technique. 
 
           
 
                 Fig.6.6 SEM image of PLGA microparticle by novel SGnPs-O-O emulsion technique. 
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SEM result show that the W-O-W emulsion gives smooth, regular surface and no pores or 
pits on the surface while W-O-O emulsion produced irregular surface having many pores 
on surface. This could be the reason for higher burst release of protein from the latter 
particles. After studying all four images it can be concluded that the presence of SGnPs in 
polymeric solution doesn’t change the surface property. Surface morphology are same for 
W-O-W and SGnPs-O-W, W-O-O and SGnPs-O-O. (Fig.6.3-6.6). 
 
6.3 Encapsulation efficiency of polymeric particle 
It was found that at very low loading (1%) show 100% EE not depends on preparation 
method, it means very low amount of protein can be completely entrapped by PLGA. As 
we increase the loading amount it shows lesser loading capacity it means up to a certain 
amount PLGA can entrap the protein not more than that but it can be increased by changing 
the particle preparation method (Table-6.1). W-O-O emulsion technique shows more 
encapsulation efficiency in comparison to W-O-W because of protein distribution (Fig.6.13 
& 6.14). Novel method (SGnPs-O-W) shows 100% EE which make it more useful tool to 
deliver growth factors. 
     Table-6.1 Encapsulation efficiency of different loading and methods 
Method 1% 5% 10% 20% 
Conventional 
Approach 
W-O-W 100 40.3 25 7 
W-O-O 100 50.59 35 28 
Novel 
Approach 
SGNPS-O-
W 
100 100 - - 
SGNPS-O-O 100 50 - - 
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  6.4 Study of release profile 
    
Fig.6.7 Release study of 5% BSA loaded PLGA particle prepared by conventional W-O-O 
emulsion method. 
 
       
Fig.6.8 Release study of 5% BSA loaded PLGA particle prepared by conventional W-O-W 
emulsion method. 
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Fig.6.9 Release study of 20 % BSA loaded PLGA particle prepared by conventional W-O-O 
emulsion method. 
          
Fig.6.10 Release study of 20% BSA loaded PLGA particle prepared by conventional W-O-W 
emulsion method. 
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Fig.6.11 Release study of 5 % BSA loaded PLGA particle prepared by novel SGNPS-O-W 
emulsion method. 
                              
Fig.6.12 Release study of 5 % BSA loaded PLGA particle prepared by novel SGNPS-O-O 
emulsion method. 
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After studying it was found that W-O-W shows less initial burst release compared to W-O-O 
emulsion technique. Reasons are discussed in morphological study (Chapter-6.2). After 
studying the release profile it was found that SGnPs-O-W shows sustained release for a long 
time. It released only 18 % of BSA in 30 days (Fig.6.11). It is because SGnPs are hydrophobic 
in nature so they don’t release protein easily in PBS and also because of surface morphology 
of particles (Fig.6.14) which is regular smooth and without any pits or pores.  
It showed very interesting release for SGnPs-O-O approach; unlike SGnPs-O-W it showed 
initial burst release and released all BSA within 7 days. (Fig.6.15). It is because continuous 
phase is oil and SGnPs are hydrophobic in nature, so SGnPs have tendency to migrate towards 
surface during preparation of secondary emulsion and also because of the surface morphology 
of particles prepared by oil in oil emulsion which creates pits and pores on surface and this is 
also a reason of low encapsulation efficiency in comparison to SGnPs-O-W.   
 
 
6.5 Protein distribution 
 
 
Fig.6.13 Fluorescent microscopic image of conventional W-O-W emulsion technique 
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       Fig.6.14 Fluorescent microscopic image of conventional W-O-O emulsion technique 
 
After study of fluorescent images it was found that BSA accumulated in the peripheral part 
of particle, while in W-O-O emulsion technique BSA was evenly distributed over the 
surface of matrix (Fig.6.13 & 6.14) because these particles were washed with n-hexane 
which is nonpolar and it is possible that surface protein was not washed and that’s may be 
a reason of initial burst release and also give a clue why W-O-O has more encapsulation 
efficiency. 
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6.6 Activity loss 
 
 
            Fig.6.15 Optimization curve for HRP activity 
 
To determine activity loss of released protein we used Horse reddish peroxidase (HRP) 
instead of BSA because BSA doesn’t show any enzymatic activity. HRP shows activity 
with OPD substrate in the presence of hydrogenperoxide. It was found that HRP extracting 
from particle over the time shows bell shape curve for activity, up to 6 hours ate activity 
increases but after 6 hours HRP release increases but activity decreases so the optimum 
incubation period is 6 hours at room temperature (250 C) (Fig. 6.15). 
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Chapter 7 
Conclusion and future work 
We have prepared PLGA micropaticles by conventional (W-O-W & W-O-O) and novel 
method (SGnPs-O-W & SGnPs-O-O). Comparative studies has shown the following 
results:  
Surface morphology of W-O-W is even, continuous and without any pores while W-O-O 
the surfaces have lot of pores that’s why W-O-O shows more burst release and no effect of 
SGnPs on the surface of particles synthesized by conventional methods (Fig.5.15 - 5.18).  
Novel method (SGnPs-O-W) is showing more protein encapsulation efficiency (100%) in 
comparison to conventional methods (W-O-W & W-O-O) so we can effectively 
encapsulate very less amount of GFs by this novel method (tab-5.2). 
SGnPs-O-W is showing sustained release of protein because the hydrophobic nature of 
SGnPs (Fig.-5.9) and this technique could be a great approach to deliver GFs for long 
duration sustain release, but when we tried SGnPs-O-O; it showed only 50% encapsulation 
efficiency (Tab-5.2) and high burst release in comparison of other process (Fig.5.10). For 
less encapsulation efficiency possible reason may be the migration of SGnPs in to the 
continuous oil phase as we know like attracts like and the remaining SGnPs may be 
arranged on the surface of PLGA matrix and showing high burst release. In future we would 
like to optimize and change the SGnPs-O-O method so we can get more encapsulation 
efficiency and sustain release.  
In near future this novel delivery system can be modified according to use or site of 
application. SGnPs can be electrospinned with polymer solution to get nanofiber scaffold, 
it can also be encapsulate in hydrogels, can be modified in to fibrous patches for dermal 
application, wound healing etc. 
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